Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Sanofi Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Sanofi şirketinin toplam hissedar öz sermayesi €73.0B ve toplam borcu €21.7B olup, bu da borç-öz sermaye oranını 29.8% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla €129.8B ve €56.8B dir. Sanofi 'in FAVÖK'ü €8.5B faiz karşılama oranı 141.6 dur. Şirketin €6.8B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

29.8%

Borç/özkaynak oranı

€21.74b

Borç

Faiz karşılama oranı	141.6x
Nakit	€6.80b
Eşitlik	€73.00b
Toplam yükümlülükler	€56.76b
Toplam varlıklar	€129.76b

Son finansal sağlık güncellemeleri

Sanofi (EPA:SAN) Seems To Use Debt Quite Sensibly

Aug 17

These 4 Measures Indicate That Sanofi (EPA:SAN) Is Using Debt Reasonably Well

Apr 13

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: SAN 'nin kısa vadeli varlıkları ( €30.1B ) kısa vadeli yükümlülüklerini ( €30.0B ) aşıyor.

Uzun Vadeli Yükümlülükler: SAN şirketinin kısa vadeli varlıkları ( €30.1B ) uzun vadeli yükümlülüklerini ( €26.7B ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: SAN 'nin net borç/öz sermaye oranı ( 20.5% ) tatmin edici olarak değerlendirilmektedir.

Borcun Azaltılması: SAN 'nin borç/öz sermaye oranı son 5 yılda 45.1% seviyesinden 29.8% seviyesine düştü.

Borç Kapsamı: SAN 'nin borcu işletme nakit akışı ( 37.3% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: SAN 'in borcuna ilişkin faiz ödemeleri EBIT ( 141.6 x kapsam) tarafından iyi bir şekilde karşılanmaktadır.

Sanofi Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Sanofi (EPA:SAN) Seems To Use Debt Quite Sensibly

These 4 Measures Indicate That Sanofi (EPA:SAN) Is Using Debt Reasonably Well

Recent updates

Sanofi Reportedly Seeks Revised Proposals for Opella

Regeneron Pharmaceuticals, Inc. and Sanofi Announce National Medical Products Administration Approves Dupixent in China

Regeneron Pharmaceuticals, Inc. and Sanofi Announce National Medical Products Administration Approves Dupixent in China

Sanofi to Report Q2, 2025 Results on Jul 31, 2025

Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Approves Dupixent (Dupilumab) as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps

Sanofi's (EPA:SAN) Earnings Haven't Escaped The Attention Of Investors

Sanofi Announces Tolebrutinib Meet Primary Endpoints in HERCULES Phase 3 Study

Sanofi (EPA:SAN) Seems To Use Debt Quite Sensibly

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Teva Pharmaceuticals and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel Disease

Sanofi Ships U.S. Influenza Vaccines for the 2024/25 Season

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Approval in the European Union as the First-Ever Targeted Therapy for Patients with COPD

Sanofi to Present New Data from its Hemophilia Portfolio at the 32nd Congress of the International Society on Thrombosis and Haemostasis

Innate Pharma and Sanofi Shares Updated Results from the Sanofi Developed Blood Cancer Phase 1/2 1/2 SAR443579/IPH6101 Trial

Regeneron Pharmaceuticals, Inc and Sanofi Announces Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation

Sarclisa Accepts for FDA Priority Review for the Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Regeneron Pharmaceuticals, Inc. and Sanofi Presents Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in the New England Journal of Medicine

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application (sBLA) for Dupixent

Upcoming dividend of €3.76 per share

Sanofi Announces Board and Committee Appointments

Sanofi Announces Board and Committee Appointments

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 17%

Sanofi Announces Quebec's INESSS Recommends BEYFORTUS® for Prevention of RSV for All Infants 8 Months of Age and Younger

These 4 Measures Indicate That Sanofi (EPA:SAN) Is Using Debt Reasonably Well

Sanofi Announces Launch of Verorab® (Sanofi Inactivated Rabies Vaccine) in the UK for Pre-exposure and Post-exposure Prophylaxis of Rabies in All Age Groups

Sanofi Announces Phase 2b Results for Amlitelimab Support Potential for Best-In-Class Maintenance of Response in Atopic Dermatitis

Full year 2023 earnings: EPS and revenues miss analyst expectations

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts Dupixent®? (Dupilumab) Sbla for Treatment of Copd with Type 2 Inflammation

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin